Webcast about the latest research breakthroughs for people living with progressive MS
Webcast about research into treatments for progressive MS
Webcast about the latest research breakthroughs for people living with progressive MS Read More »
Research
Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports
Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.
MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity
Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found.
MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity Read More »
Multiple Sclerosis Drugs Might Not Need To Reach the Brain To Have Clinical Efficacy
Source Technology Networks: Scientists from Trinity College Dublin have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS) and other autoimmune diseases such as psoriasis and rheumatoid arthritis.
Multiple Sclerosis Drugs Might Not Need To Reach the Brain To Have Clinical Efficacy Read More »
Gene Variants Linked to High Childhood BMI Point to Higher MS Risk, Study Finds
Source Multiple Sclerosis News Today: Genetic variations that increase body mass index (BMI) in childhood are associated with a higher risk of multiple sclerosis (MS) regardless of a person’s vitamin D levels, a study found.
Gene Variants Linked to High Childhood BMI Point to Higher MS Risk, Study Finds Read More »
Sanofi MS drug results set stage for extensive late-stage testing
Source Biopharmadive.com: With positive results from a mid-stage study in hand, Sanofi is pushing an experimental multiple sclerosis drug into an extensive late-stage research program comprised of four studies scheduled to begin in the middle of this year.
Sanofi MS drug results set stage for extensive late-stage testing Read More »
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART)
Source The Lancet: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource.
Siponimod licensed for secondary progressive MS
Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease.
Siponimod licensed for secondary progressive MS Read More »